These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 28320454)

  • 1. Mitigation of disease- and treatment-related risks in patients with psoriatic arthritis.
    Bergman M; Lundholm A
    Arthritis Res Ther; 2017 Mar; 19(1):63. PubMed ID: 28320454
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Psoriatic disease--from skin to bone.
    Ritchlin C
    Nat Clin Pract Rheumatol; 2007 Dec; 3(12):698-706. PubMed ID: 18037929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Role of Tumor Necrosis Factor-α Blockers in Psoriatic Disease. Therapeutic Options in Psoriatic Arthritis.
    Addimanda O; Possemato N; Caruso A; Pipitone N; Salvarani C
    J Rheumatol Suppl; 2015 Nov; 93():73-8. PubMed ID: 26523063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive treatment of psoriatic arthritis: managing comorbidities and extraarticular manifestations.
    Ogdie A; Schwartzman S; Eder L; Maharaj AB; Zisman D; Raychaudhuri SP; Reddy SM; Husni E
    J Rheumatol; 2014 Nov; 41(11):2315-22. PubMed ID: 25362717
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comorbidities in Psoriatic Arthritis.
    Husni ME
    Rheum Dis Clin North Am; 2015 Nov; 41(4):677-98. PubMed ID: 26476226
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Psoriatic arthritis: complexities, comorbidities and implications for the clinic.
    Haroon M; FitzGerald O
    Expert Rev Clin Immunol; 2016; 12(4):405-16. PubMed ID: 26735626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of Agents other than Tumor Necrosis Factor Blockers in the Treatment of Psoriatic Arthritis.
    Atzeni F; Costa L; Caso F; Scarpa R; Sarzi-Puttini P
    J Rheumatol Suppl; 2015 Nov; 93():79-81. PubMed ID: 26523064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Update on anti-tumor necrosis factor therapy in the spondyloarthropathies including psoriatic arthritis.
    Kavanaugh A; Tutuncu Z; Catalan-Sanchez T
    Curr Opin Rheumatol; 2006 Jul; 18(4):347-53. PubMed ID: 16763453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infliximab in psoriasis and psoriatic arthritis.
    Papoutsaki M; Osório F; Morais P; Torres T; Magina S; Chimenti S; Costanzo A
    BioDrugs; 2013 Jan; 27 Suppl 1():13-23. PubMed ID: 23990278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Etanercept in the treatment of psoriatic arthritis.
    Puig L; López-Ferrer A; Laiz A
    Actas Dermosifiliogr; 2015 May; 106(4):252-9. PubMed ID: 25455504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current concepts in psoriatic arthritis: pathogenesis and management.
    de Vlam K; Gottlieb AB; Mease PJ
    Acta Derm Venereol; 2014 Nov; 94(6):627-34. PubMed ID: 24573106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Leflunomide in psoriatic arthritis.
    Kaltwasser JP
    Autoimmun Rev; 2007 Sep; 6(8):511-4. PubMed ID: 17854740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recognizing and managing comorbidities in psoriatic arthritis.
    Ogdie A; Schwartzman S; Husni ME
    Curr Opin Rheumatol; 2015 Mar; 27(2):118-26. PubMed ID: 25603040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Apremilast for the treatment of psoriatic arthritis.
    Martin BC; Thomas LW; Dann FJ
    Dermatol Online J; 2017 Feb; 23(2):. PubMed ID: 28329487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A review of disease activity measures for psoriatic arthritis: what is the best approach?
    Her M; Kavanaugh A
    Expert Rev Clin Immunol; 2014 Sep; 10(9):1241-54. PubMed ID: 25088300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Psoriatic arthritis : Overview of drug therapy options and administration characteristics].
    Behrens F; Thaçi D; Wollenhaupt J; Krüger K
    Hautarzt; 2017 Feb; 68(2):153-169. PubMed ID: 28083597
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How effective is ustekinumab in controlling psoriatic arthritis?
    Bonifati C; Graceffa D
    Dermatol Ther; 2016 May; 29(3):155-9. PubMed ID: 26626908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disease-modifying antirheumatic drugs other than methotrexate in rheumatoid arthritis and seronegative arthritis.
    Nandi P; Kingsley GH; Scott DL
    Curr Opin Rheumatol; 2008 May; 20(3):251-6. PubMed ID: 18388514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early psoriatic arthritis.
    Gladman DD
    Rheum Dis Clin North Am; 2012 May; 38(2):373-86. PubMed ID: 22819090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence and Prevalence of Cardiovascular Risk Factors Among Patients With Rheumatoid Arthritis, Psoriasis, or Psoriatic Arthritis.
    Radner H; Lesperance T; Accortt NA; Solomon DH
    Arthritis Care Res (Hoboken); 2017 Oct; 69(10):1510-1518. PubMed ID: 27998029
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.